Výsledky vyhledávání - "David R. Rutledge"

Clinical outcomes in real-world patients with bifurcation lesions receiving Xience V everolimus-eluting stents: Four-year results from the Xience V USA study

Autor: Krishnankutty Sudhir, Kalyan Kakarala, David R. Rutledge, James B. Hermiller, Michael M. Butler, Colleen Baird, Mitchell W. Krucoff, Jin Wang, Robert J. Applegate

Publikováno v: Catheterization and Cardiovascular Interventions. 88:62-70

Background The Xience V USA Study demonstrated safety and efficacy of the XIENCE V® everolimus-eluting stent (EES) in a large, prospective study of a real-world, unselected patient population. There is limited long-term data regarding EES performanc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::28065228e025a2bb747d34f718e06871
https://doi.org/10.1002/ccd.26217

Zobrazit plný text záznamu

Safety and Effectiveness of Everolimus-Eluting Stents in Chronic Total Coronary Occlusion Revascularization

Autor: William Lombardi, Jeffrey J. Popma, David R. Rutledge, William J. Nicholson, Jin Wang, Pradyumna E. Tummala, J. Aaron Grantham, David E. Kandzari, Annapoorna Kini, Nicholas Lembo, Charles Orr, Dimitri Karmpaliotis, Cristina Larracas, Jeffrey W. Moses

Publikováno v: JACC: Cardiovascular Interventions. 8:761-769

Objectives This study sought to evaluate procedural and clinical outcomes among patients undergoing chronic total occlusion (CTO) percutaneous coronary intervention (PCI) using contemporary methods and everolimus-eluting stents (EES). Background Limi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f76dff3e5c71cb8e5b15b1278a4b137e
https://doi.org/10.1016/j.jcin.2014.12.238

Zobrazit plný text záznamu

Clinical outcomes in real‐world patients with small vessel disease treated with XIENCE V ® everolimus‐eluting stents: One year results from the XIENCE V ® USA condition of approval post‐market study

Autor: Samin K. Sharma, Vivian W. Mao, William Lombardi, James B. Hermiller, David R. Rutledge, Jin Wang, Mitchell W. Krucoff, Weiying Zhao, Luis Gruberg

Publikováno v: Catheterization and Cardiovascular Interventions. 84:7-16

Objectives The purpose of this study was to evaluate the 1-year clinical outcomes of more complex XIENCE V USA real-world patients with small versus nonsmall vessel lesions. Background Patients with small vessel lesions undergoing coronary stent plac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::aca7f04703c7e32ae6805d68f37e71d6
https://doi.org/10.1002/ccd.25325

Zobrazit plný text záznamu

Contemporary Incidence and Predictors of Stent Thrombosis and Other Major Adverse Cardiac Events in the Year After XIENCE V Implantation

Autor: Charles A. Simonton, Krishnankutty Sudhir, Srihari S. Naidu, Weiying Zhao, Vivian W. Mao, Olivia Wilburn, David R. Rutledge, Mitchell W. Krucoff, James B. Hermiller, Qing Zheng

Publikováno v: JACC: Cardiovascular Interventions. 5(6):626-635

Objectives: The aim of this study was to identify predictors of clinical events after XIENCE V (Abbott Vascular, Santa Clara, California) stenting.Background: The XIENCE V USA (XIENCE V Everolimus ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb68c8f82c884ab73636a89bb60b0965

Zobrazit plný text záznamu

A New Era of Prospective Real-World Safety Evaluation

Autor: Samin K. Sharma, Charles A. Simonton, Lalitha Jonnavithula, Weiying Zhao, James B. Hermiller, Vivian W. Mao, Jin Wang, Luis Gruberg, William Lombardi, Olivia Wilburn, John N. Katopodis, David R. Rutledge, Mitchell W. Krucoff, Hoshedar P. Tamboli, Krishnankutty Sudhir

Publikováno v: JACC: Cardiovascular Interventions. 4(12):1298-1309

The XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System Condition-of-Approval Post-Market Study) sought to evaluate the safety of everolimus-eluting coronary stent systems in a real-world population with a total of 5,054 participants (1,8

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9d054e09c8a5e773302988daf8d082c

Zobrazit plný text záznamu

Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents Insights From the Xience V Coronary Stent System Trials

Autor: Adriano Caixeta, Gregg W. Stone, Charles A. Simonton, Patrick W. Serruys, Elvin Kedhi, Jennifer Jones-McMeans, Philippe Généreux, David R. Rutledge, Mitchell W. Krucoff, James B. Hermiller, Krishnankutty Sudhir, Jin Wang, Tullio Palmerini

Publikováno v: Circulation-cardiovascular interventions, 8(5). Lippincott Williams & Wilkins

Background— Whether premature dual antiplatelet therapy (DAPT) interruption is safe in patients receiving cobalt chromium everolimus–eluting stents remains controversial. We sought to examine the relationship between DAPT discontinuation and sten

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71bf6c20b93ddda3e9e96119d5f5ef03
https://doi.org/10.1161/circinterventions.114.001362

Zobrazit plný text záznamu

TCT-39 Long-term Clinical Outcomes in Real-World Patients with Acute Myocardial Infarction Receiving XIENCE V® Everolimus-Eluting Stents: Four-Year Results from the XIENCE V USA Study

Autor: Sherry Cao, Vivian W. Mao, Krishnankutty Sudhir, David R. Rutledge

Publikováno v: Journal of the American College of Cardiology. 64(11)

XIENCE V USA is a prospective, multicenter, single-arm, FDA condition- of-approval study to evaluate the safety and effectiveness of the XIENCE V® Everolimus Eluting Stent (XIENCE V, Abbott Vascular, Santa Clara, CA) in a real-world, all-comer popul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f985e8027a8d287cf98dabfd23c9d62f

Zobrazit plný text záznamu

Applying Managed Care Performance Measures in Community Pharmacy-Based Outcomes Research

Autor: David R. Rutledge, Kristina M. Cap

Publikováno v: Journal of the American Pharmaceutical Association (1996). 39:388-394

Objective: (1) To introduce the National Committee on Quality Assurance's (NCQA's) Health Employer Data and Information Set (HEDIS), a set of managed care performance measures, as a tool for conducting outcomes research in the community pharmacy; (2)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cebd5dffb18271b8348f62c1b34290b9
https://doi.org/10.1016/s1086-5802(16)30435-1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání